Journal article

Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study

TME Davis, R Ting, JD Best, MW Donoghoe, PL Drury, DR Sullivan, AJ Jenkins, RL O'Connell, MJ Whiting, PP Glasziou, RJ Simes, YA Kesaniemi, VJ Gebski, RS Scott, AC Keech

Diabetologia | SPRINGER | Published : 2011


Funding Acknowledgements

The study was designed by an independent Management Committee and coordinated by the National Health and Medical Research Council (NHMRC) Clinical Trials Centre, University of Sydney, NSW, Australia. The FIELD study was supported by grants from Laboratoires Fournier, Dijon, France (now part of Abbott Pharmaceuticals) and the NHMRC of Australia (Unit grant, Project grant and Fellowships to A. C. Keech and R. J. Simes). Two non-voting representatives of the main sponsor attended meetings of the Management Committee. Study sponsors had no role in data collection or analysis. The authors had full access to all study data. T. M. E. Davis is supported by an NHMRC Practitioner Fellowship. R. Ting is supported by a University of Sydney Clinical Trials Centre scholarship. We thank the National Heart Foundation, Australia, Diabetes Australia, Diabetes New Zealand and the Finnish Diabetes Association for endorsing the study. We also thank R. Pike (NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia) for her assistance with preparation of this manuscript and J.-C. Ansquer for helpful comments. Thanks also go to the many patients and investigators who participated in the FIELD Study.Some authors have been reimbursed by the pharmaceutical industry for the costs of participating in scientific meetings, contributing to advisory boards, or doing other research: T. M. E. Davis (sanofi-aventis, Novartis, NovoNordisk, Merck Sharpe & Dohme, Bristol-Myer Squibb, Solvay, GlaxoSmithKline, Pfizer), R. Ting (Solvay (now Abbott), Servier), P. L. Drury (lecture fees from Eli Lilly), D. R. Sullivan (Solvay (now Abbott), AstraZeneca, Merck Sharpe & Dohme, Pfizer, Schering Plough), A. J. Jenkins (Medtronic, Merck, Pfizer, sanofi-aventis, Solvay (now Abbott)), R. J. Simes (research grant to University of Sydney from Laboratoires Fournier SA), Y. A. Kesaniemi (research grant from Merck/Schering Plough, Novartis and Fournier; honoraria and/or cost reimbursement for scientific meetings participation from Fournier and Merck/Schering Plough; support for participating in advisory board meetings for Merck/Schering Plough and AstraZeneca) and A. C. Keech (Merck, Bristol-Myer Squibb, Abbott, Banyu, Eli Lilly, Novartis, AstraZeneca, Solvay (now Abbott), Roche Diagnostics, Novo Nordisk, Roche, and research grant to University of Sydney from Laboratoires Fournier SA). Y. A. Kesaniemi holds stocks in Orion Pharma. All other authors declare that there is no duality of interest associated with this manuscript.